Suppr超能文献

用辛伐他汀处理的人冠状动脉内皮细胞的时间基因表达分析

Temporal gene expression analysis of human coronary artery endothelial cells treated with Simvastatin.

作者信息

Zhang Li Qin, Ma Shwu-Fan, Grigoryev Dmitry, Lavoie Tera L, Xiao Hui Qing, Setterquist Robert, Li Hailong, Jacobson Jeffrey, Garcia Joe G N, Ye Shui Qing

机构信息

Department of Surgery and Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65212, USA.

出版信息

Gene Expr. 2008;14(4):229-39. doi: 10.3727/105221608786883834.

Abstract

Increasing evidence indicates that the beneficial "pleiotropic" effects of statins on clinical events involve nonlipid mechanisms including the modification of blood vessel endothelial cell function. However, the involved molecular events and pathways are not completely understood. In the present study, Affymetrix microarrays were used to monitor the temporal gene expression of human coronary artery endothelial cells (HCAEC) treated with simvastatin (Sim) to gain insight into statins' direct effects on the endothelial function. We isolated and labeled mRNA from HCAEC treated with Sim for 0, 3, 6, 12, 24, and 48 h and hybridized these samples to Affymetrix GeneChip HG-U95Av2 to analyze the temporal gene expression profile. Out of 12,625 genes present on the HG-U95Av2 GeneChip, expression of 5,432 genes was detected. There were 1,475 of 5,432 genes that displayed the differential expression compared to baseline (0 h). Fifty-four genes were upregulated (< or = twofold) while 61 genes were downregulated ( > or = twofold) at 24-48 h after the Sim treatment. Many new target genes and pathways modulated by Sim were uncovered. This study indicates that many aspects of the pleiotropic effect of Sim on the endothelial cell function can be mediated by transcriptional control. Physiological function of 22% of 115 differentially expressed genes in Sim-treated HCAEC are currently unknown. These newly identified genes could be useful for new mechanistic study and new therapeutic modalities. Expressions of 13 out of 18 genes (> 70%) in the cell cycle/proliferation control process were significantly inhibited by the Sim treatment. CDC25B and ITGB4 gene expressions were validated by RT-PCR and Western blotting. Sim's inhibitory effect of on HCAEC growth was confirmed by the measurement of [3H]thymidine incorporation into the DNA synthesis. Further in-depth analysis of this effect may shed light on molecular mechanisms of Sim's beneficial inhibition of neointima formation in the atherosclerotic artery stenosis.

摘要

越来越多的证据表明,他汀类药物对临床事件有益的“多效性”作用涉及非脂质机制,包括血管内皮细胞功能的改变。然而,所涉及的分子事件和途径尚未完全明确。在本研究中,使用Affymetrix微阵列监测用辛伐他汀(Sim)处理的人冠状动脉内皮细胞(HCAEC)的基因表达随时间的变化,以深入了解他汀类药物对内皮功能的直接作用。我们从用Sim处理0、3、6、12、24和48小时的HCAEC中分离并标记mRNA,并将这些样品与Affymetrix GeneChip HG-U95Av2杂交,以分析基因表达随时间的变化情况。在HG-U95Av2基因芯片上的12,625个基因中,检测到5,432个基因的表达。与基线(0小时)相比,5,432个基因中有1,475个表现出差异表达。在Sim处理后24 - 48小时,54个基因上调(≤两倍),61个基因下调(≥两倍)。发现了许多由Sim调节的新靶基因和途径。本研究表明,Sim对内皮细胞功能多效性作用的许多方面可通过转录调控介导。在Sim处理的HCAEC中,115个差异表达基因中有22%的生理功能目前尚不清楚。这些新鉴定的基因可能有助于新的机制研究和新的治疗方法。在细胞周期/增殖控制过程中,18个基因中有13个(>70%)的表达受到Sim处理的显著抑制。通过RT-PCR和蛋白质印迹法验证了CDC25B和ITGB4基因的表达。通过测量[3H]胸苷掺入DNA合成,证实了Sim对HCAEC生长的抑制作用。对这种作用的进一步深入分析可能有助于揭示Sim在动脉粥样硬化性动脉狭窄中有益抑制新生内膜形成的分子机制。

相似文献

2
Simvastatin improves diabetes-induced coronary endothelial dysfunction.
J Pharmacol Exp Ther. 2006 Oct;319(1):386-95. doi: 10.1124/jpet.106.106823. Epub 2006 Jul 18.
6
Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma.
Neuroendocrinology. 2024;114(10):934-949. doi: 10.1159/000539821. Epub 2024 Jul 22.

引用本文的文献

1
Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.
Antioxid Redox Signal. 2014 Mar 10;20(8):1198-215. doi: 10.1089/ars.2013.5430. Epub 2014 Jan 3.
2
Critical role for integrin-β4 in the attenuation of murine acute lung injury by simvastatin.
Am J Physiol Lung Cell Mol Physiol. 2012 Aug 15;303(4):L279-85. doi: 10.1152/ajplung.00361.2011. Epub 2012 Jun 8.

本文引用的文献

1
Primary prevention of coronary artery disease.
N Engl J Med. 2007 Oct 11;357(15):1543-5. doi: 10.1056/NEJMe078183.
2
Long-term follow-up of the West of Scotland Coronary Prevention Study.
N Engl J Med. 2007 Oct 11;357(15):1477-86. doi: 10.1056/NEJMoa065994.
4
Influence of statin use on endothelial function: from bench to clinics.
Curr Pharm Des. 2007;13(17):1771-86. doi: 10.2174/138161207780831220.
5
Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?
Expert Opin Pharmacother. 2007 Jun;8(9):1235-43. doi: 10.1517/14656566.8.9.1235.
7
Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Nat Clin Pract Cardiovasc Med. 2006 Dec;3(12):664-72. doi: 10.1038/ncpcardio0711.
8
Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the rotterdam study and a meta-analysis.
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):212-7. doi: 10.1161/01.ATV.0000194099.65024.17. Epub 2005 Nov 3.
9
Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers.
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):194-9. doi: 10.1161/01.ATV.0000191633.52585.14. Epub 2005 Oct 20.
10
Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.
Microvasc Res. 2005 Nov;70(3):142-51. doi: 10.1016/j.mvr.2005.08.003. Epub 2005 Sep 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验